Form 4 Filing for Nuvation Bio Inc.

On April 17, 2026, Wentworth Kerry, Chief Regulatory Officer of Nuvation Bio Inc. (NUVB), reported a series of transactions. Kerry acquired 36,750 shares of Class A Common Stock at a price of $2.93 per share. Concurrently, Kerry sold 36,750 shares of Class A Common Stock at a weighted-average price of $5.0144 per share, with individual sales prices ranging from $5.00 to $5.05. These sales were conducted under a 10b5-1 plan initiated on December 4, 2025. Additionally, Kerry exercised a stock option to buy 36,750 shares of Class A Common Stock at an exercise price of $2.93 per share, with the option vesting over time starting August 29, 2022. Following these transactions, Kerry directly holds 53,000 shares of Class A Common Stock.